A meta-analysis of efficacy of Morus alba Linn. to improve blood glucose and lipid profile

European Journal of Nutrition

Volumn 56, Issue 4, 2017, Pages 1509-1521

  Phimarn, Wiraphol ^a   Wichaiyo, Kittisak ^a   Silpsavikul, Khuntawan ^a   Sungthong, Bunleu ^a   Saramunee, Kritsanee ^a  

^a MAHASARAKHAM UNIVERSITY   (Thailand)

Author keywords

Blood glucose; Blood lipid; Diabetes mellitus; Dyslipidaemia; Mulberry (Morus alba)

Indexed keywords

1 DEOXYNOJIRIMYCIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; MULBERRY EXTRACT; PLACEBO; TRIACYLGLYCEROL; UREA; GLYCOSYLATED HEMOGLOBIN; PLANT EXTRACT;

ADVERSE OUTCOME; ARTICLE; ASSESSMENT OF HUMANS; CLINICAL EVALUATION; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; DATA BASE; DIARRHEA; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HEADACHE; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; JADAD SCORE; LIPID BLOOD LEVEL; MEDLINE; META ANALYSIS; MORUS ALBA; NAUSEA; PLANT LEAF; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCIENCEDIRECT; SCORING SYSTEM; SYSTEMATIC REVIEW; UREA NITROGEN BLOOD LEVEL; BLOOD; CHEMISTRY; METABOLISM; MORUS; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE;

BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; GLYCATED HEMOGLOBIN A; HUMANS; MORUS; PLANT EXTRACTS; POSTPRANDIAL PERIOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIGLYCERIDES;

EID: 84961148224     PISSN: 14366207     EISSN: 14366215     Source Type: Journal    
DOI: 10.1007/s00394-016-1197-x     Document Type: Article

References (49)

1. Falko M (2011) Balancing efficacy and tolerability issues with Statin Therapy—Considerations for the use of Pitavastatin in special patient populations. US Endocrinol 7:30–39. doi:10.17925/USE.2011.07.01.30
2. WHO (2015) Cardiovascular diseases (CVDs), Fact Sheet, 2009. http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed August 15, 2015
3. Musunuru K (2010) Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids 45:907–914
4. Assmann G, Cullen P, Schulte H (2010) Non-LDL-related dyslipidemia and coronary risk: a case-control study. Diab Vasc Dis Res 7:204–212
5. Davidson JA, Parkin CG (2009) Is hyperglycemia a causal factor in cardiovascular disease? Diab Care 32:s331–s333
6. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A, Watts GF (2011) Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 32:1345–1361
7. Tian L, Liu Y, Qin Y, Long S, Xu Y, Fu M (2010) Association of the low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio and concentrations of plasma lipids with high-density lipoprotein subclass distribution in the Chinese population. Lipids Health Dis 9:1–10. doi:10.1186/1476-511X-9-69
8. Wu T, Fu J, Yang Y, Zhang L, Han J (2009) The effects of phytosterols/stanols on blood lipid profiles: a systematic review with meta-analysis. Asia Pac J Clin Nutr 18:179–186
9. Derosa G, Sibilla S (2007) Optimizing combination treatment in the management of type 2 diabetes. Vasc Health Risk Manag 3:665–671
10. Schuck RN, Mendys PM, Simpson RJ Jr (2013) Beyond statins: lipid management to reduce cardiovascular risk. Pharmacotherapy 33:754–764
11. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM (2007) A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diab Care 30:389–394
12. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE (2003) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Arch Int Med 163:2594–2602
13. Vermes A, Vermes I (2004) Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs 4:247–255
14. Golomb BA, Evans MA (2008) Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 8:373–418
15. Aramwit P, Supasyndh O, Siritienthong T, Bang N (2013) Mulberry leaf reduces oxidation and C-reactive protein level in patients with mild dyslipidemia. Biomed Res Int. doi:10.1155/2013/787981
16. Asai A, Nakagawa K, Higuchi O, Kimura T, Kojima Y, Kariya J, Miyazawa T, Oikawa S (2011) Effect of mulberry leaf extract with enriched 1-deoxynojirimycin content on postprandial glycemic control in subjects with impaired glucose metabolism. J Diab Invest 2:318–323
17. Kim JY, Ok HM, Kim J, Park SW, Kwon SW, Kwon O (2015) Mulberry leaf extract improves postprandial glucose response in prediabetic subjects: a randomized, double-blind placebo-controlled trial. J Med Food 18:306–313
18. Choonwatchana N, Malaisit D (2015) Effect of mulberry leaf extract capsule on blood lipid profile of dyslipidemic patients. Dessertation. Mahasarakham University
19. Trimarco V, Izzo R, Stabile E, Rozza F, Santoro M, Manzi MV, Serino F, Giacomo SG, Esposito G, Trimarco B (2015) Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endothelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial. High Blood Press Cardiovasc Prev 22:149–154
20. Chung HI, Kim J, Kim JY, Kwon O (2013) Acute intake of mulberry leaf aqueous extract affects postprandial glucose response after maltose loading: randomized double-blind placebo-controlled pilot study. J Funct Foods 13:1502–1506
21. Kim HJ, Yoon KH, Kang MJ, Yim HW, Lee KS, Vuksan V, Sung MK (2012) A six-month supplementation of mulberry, Korean red ginseng, and banana decreases biomarkers of systemic low-grade inflammation in subjects with impaired glucose tolerance and type 2 diabetes. Evid Based Complement Alternat Med. doi:10.1155/2012/735191
22. Higgins J, Green SE (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. http://http://handbook.cochrane.org/ Accessed 12 November, 2014
23. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. doi:10.1136/bmj.b2535
24. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12
25. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. doi:10.1136/bmj.d5928
26. The JAMA network (2000) SI conversion calculator. JAMA 283:134–135
27. Egger M, Davey-Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
28. Kimura T, Nakagawa K, Kubota H, Kojima Y, Goto Y, Yamagishi K, Oita S, Oikawa S, Miyazawa T (2007) Food-grade mulberry powder enriched with 1-deoxynojirimycin suppresses the elevation of postprandial blood glucose in humans. J Agric Food Chem 55:5867–5874
29. Mudra M, Ercan-Fang N, Zhong L, Furne J, Levitt M (2007) Influence of mulberry leaf extract on the blood glucose and breath hydrogen response to ingestion of 75 g sucrose by type 2 diabetic and control subjects. Diab Care 30:1272–1274
30. Nakamura S, Hashiguchi M, Yoshihiko Y, Oku T (2011) Hypoglycemic effects of Morus alba leaf extract on postprandial glucose and insulin levels in patients with type 2 diabetes treated with sulfonylurea hypoglycemic agents. J Diab Metab. doi:10.4172/2155-6156.1000158
31. Sukriket P, Lookhanumanjao S, Bumrungpert A (2014) The effect of mulberry leaf tea on postprandial glycemic control and insulin sensitivity in pre-diabetic and non-diabetic subjects. http://www.mfu.ac.th/school/anti-aging/File_PDF/Research_PDF55/Proceeding_15.pdf. Accessed 15 Dec 2014
32. Banu S, Jabir NR, Manjunath NC, Khan MS, Ashraf GM, Kamal MA, Tabrez S (2015) Reduction of post-prandial hyperglycemia by mulberry tea in type-2 diabetes patients. Saudi J Biol Sci 22:32–36
33. Banchobphutsa Y, Jarasphol R (2014) The efficacy of Morus alba leaf tea in patents with dyslipidemia. http://www.mfu.ac.th/school/anti-aging/File_PDF/Research_PDF55/Proceeding_7.pdf. Accessed 15 Dec, 2014
34. Hu M, Zeng W, Tomlinson B (2014) Evaluation of a crataegus-based multiherb formula for dyslipidemia: a randomized, double-blind, placebo-controlled clinical trial. Evid Based Complement Alternat. doi:10.1155/2014/365742
35. World Health Organisation (2000) General guidelines for methodologies on research and evaluation of traditional medicine. World Health Organisation, Geneva
36. Hansawasdi C, Kawabata J (2006) Alpha-glucosidase inhibitory effect of mulberry (Morus alba) leaves on Caco-2. Fitoterapia 77:568–573
37. Habeeb MN, Naik PR, Moqbel FS (2012) Inhibition of α-glucosidase and α-amylase by Morus alba linn leaf extracts. J Pharm Res 5:285–289
38. Vichasilp C, Nakagawa K, Sookwong P, Higuchi O, Kimura F, Miyazawa T (2012) A novel gelatin crosslinking method retards release of mulberry 1-deoxynojirimycin providing a prolonged hypoglycaemic effect. Food Chem 134:1823–1830
39. Asano N, Yamashita T, Yasuda K, Ikeda K, Kizu H, Kameda Y, Kato A, Nash RJ, Lee HS, Ryu KS (2011) Polyhydroxylated alkaloids isolated from mulberry trees (Morus alba L.) and silkworms (Bombyx mori L.). J Agric Food Chem 49:4208–4213
40. Nakagawa K (2013) Studies targeting α-glucosidase inhibition, antiangiogenic effects, and lipid modification regulation: background, evaluation, and challenges in the development of food ingredients for therapeutic purposes. Biosci Biotechnol Biochem 77:900–908
41. Lown M, Fuller R, Lightowler H, Fraser A, Gallagher A, Stuart B, Byrne CD, Lewith G (2015) Mulberry extract to modulate blood glucose responses in noRmoglYcaemic adults (MULBERRY): study protocol for a randomised controlled trial. Trials 16:486
42. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486–494
43. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M (2004) Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25:10–16
44. Chen JM, Chang CW, Lin YC, Horng JT, Sheu WH (2014) Acarbose treatment and the risk of cardiovascular disease in type 2 diabetic patients: a nationwide seven-year follow-up study. J Diab Res. doi:10.1155/2014/812628
45. Yu PC, Bosnyak Z, Ceriello A (2010) The importance of glycated haemoglobin (HbA1c) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with type 2 diabetes. Diab Res Clin Pract 89(1):1–9
46. Shishtar E, Sievenpiper JL, Djedovic V, Cozma AI, Ha V, Jayalath VH, Jenkins DJ, Meija SB, de Souza RJ, Jovanovski E, Vuksan V (2014) The effect of ginseng (The Genus Panax) on glycemic control: a systematic review and meta-analysis of randomized controlled clinical trials. PLoS ONE. doi:10.1371/journal.pone.0107391
47. Kong WH, Oh SH, Ahn YR, Kim KW, Kim JH, Seo SW (2008) Antiobesity effects and improvement of insulin sensitivity by 1-deoxynojirimycin in animal models. J Agric Food Chem 56:2613–2619
48. Suo HS, Yan YH, Ko CH, Chen KM, Lee SC, Liu CT (2014) A comparison of food-grade folium mori (Sāng Yè) extract and 1-deoxynojirimycin for glycemic control and renal function in streptozotocin-induced diabetic rats. J Tradit Complement Med 4:162–170
49. Kojima Y, Kimura T, Nakagawa K, Asai A, Hasumi K, Oikawa S, Miyazawa T (2010) Effects of mulberry leaf extract rich in 1-deoxynojirimycin on blood lipid profiles in human. J Clin Biochem Nutr 47:155–161